Biotecnol Limited is a privately held company backed by private investment, and its main shareholder is the Biotecnol Group (PT). In late 2011 and early 2012, Biotecnol succeeded in raising two additional rounds of seed funding from other private sources and has therefore secured the necessary funding for starting its activities and acquiring key assets for building a pipeline of innovative therapeutic products.

Furthermore, the company successfully managed to cash-in on the out-licensing of its non-core product assets (non-Tribody products in pre-clinical development) and top-up the initial investment. Through additional licensing and partnership deals around its Tribody platform, Biotecnol, Inc. was able to secure additional non-diluting funding that has enabled the company to continue developing its core product assets in the pre-clinical setting.